SCHEMBL5098764

SCHEMBL5098764

COC(=O)c1ccc(-c2cc(C(=O)O)ccc2C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.54
GRIK1 P39086 1/20 0.54
GRIA1 P42261 1/20 0.54
GRIA2 P42262 1/20 0.54
GRIA3 P42263 1/20 0.54
GRIA4 P48058 1/20 0.54
TDP1 Q9NUW8 1/20 0.50
SLC2A1 P11166 1/20 0.49
PTGS2 P35354 1/20 0.48
TSHR P16473 1/20 0.47
MAPK14 Q16539 3/20 0.47
KDM4E B2RXH2 2/20 0.46
KDM6B O15054 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
KDM3A Q9Y4C1 1/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA12 O43570 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2342676 0.94 PTGS2 (0.51) EGFRGRIK1GRIA1GRIA2GRIA3
SCHEMBL22292439 0.88 KDM4E (0.54) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL26878712 0.87 EGFR (0.54) EGFRTDP1SLC2A1PTGS2TSHR
SCHEMBL28905197 0.87 SLC2A1 (0.59) EGFRTDP1SLC2A1PTGS2TSHR
SCHEMBL4603074 0.86 GRIK1 (0.62) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL821283 0.85 PTGS2 (0.59) EGFRTDP1SLC2A1PTGS2TSHR
SCHEMBL2347043 0.84 CA12 (0.51) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL28956464 0.84 EGFR (0.54) EGFRTDP1SLC2A1PTGS2TSHR
SCHEMBL2744548 0.84 CA1 (0.59) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL6746900 0.83 MAPK14 (0.61) MAPK14KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626055-B2 Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-12-01 US disclosed
US-7626055-B2 Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-12-01 US disclosed
US-7396843-B2 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2008-07-08 US disclosed
US-7396843-B2 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2008-07-08 US disclosed
US-7396843-B2 5′-carbamoyl-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2008-07-08 US disclosed
US-7271289-B2 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-09-18 US disclosed
US-7271289-B2 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-09-18 US disclosed
US-20070105850-A1 Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-05-10 US disclosed
US-20070105850-A1 Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2007-05-10 US disclosed
US-7208629-B2 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-04-24 US disclosed
US-7208629-B2 5′-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-04-24 US disclosed
EP-1611085-B1 BIPHENYL-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-02-28 EP disclosed
US-20050038014-A1 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2005-02-17 US disclosed
US-20040267012-A1 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2004-12-30 US disclosed
EP-1435933-A1 5'-CARBAMOYL-2'-METHYL-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
EP-1435936-A1 5'-CARBAMOYL-1,1-BIPHENYL-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
EP-1435942-A1 5'-CARBAMOYL-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
WO-2003032970-A1 5'-CARBAMOYL-2'-METHYL-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed
WO-2003032972-A1 5’-CARBAMOYL-1,1-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed
WO-2003032980-A1 5'-CARBAMOYL-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267012-A1 5'-Carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors MAPK4, GRK4, NR4A1 EGFR 396/4885GRIK1 628/4885GRIA1 537/4885
US-20050038014-A1 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors MAPK1, MAP4K2, MAP3K1 EGFR 522/4885GRIK1 588/4885GRIA1 1429/4885
US-20070105850-A1 Biphenyl-carboxamide derivatives and their use as p38 kinase inhibitors MAPK1, MAPKAPK2, MAP3K8 EGFR 341/4885GRIK1 787/4885GRIA1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.